Compare General Dynamics Corporation (GD) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Summit Therapeutics Inc — how do they compare? General Dynamics Corporation trades at $365.8 (market cap $98.88B), while Summit Therapeutics Inc trades at $13.77 (market cap $11.70B). The key difference: General Dynamics Corporation is far larger — about 8.5× Summit Therapeutics Inc's market cap, and General Dynamics Corporation pays a 1.74% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| GD | SMMT | |
|---|---|---|
Market Cap | $98.88B | $11.70B |
Sector | Industrials | Health |
52-Week High | $376.88 | $29.32 |
52-Week Low | $297.05 | $13.05 |
Enterprise Value | $105.06B | $11.12B |
Dividend Yield | 1.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $366.40, down 0.84% on the day, with strong technical momentum indicated by bullish moving averages and oscillators. The company demonstrates solid fundamentals with Q1 2026 EPS beating expectations at $4.10 versus $3.67, continuing a trend of earnings outperformance. Revenue growth has been consistent, reaching $52.55 billion in 2025 with an 8.07% net income margin. Analyst sentiment remains positive with a $395.83 consensus price target and 53% buy ratings.
The outlook for GD is favorable given strong defense spending tailwinds and a growing $130.8 billion backlog, particularly in marine systems. However, risks include execution challenges on large contracts and potential defense budget volatility. The stock's current valuation at 23x P/E appears reasonable relative to earnings growth prospects, positioning it as a core defense holding for long-term investors.
Summit Therapeutics (SMMT) trades at $13.90, down 10.15% today, reflecting market reaction to mixed earnings and high volatility. The technical picture is bearish with weak moving averages, while fundamentals show significant losses with a net income of -$1.08B in 2025 and negative ROE/ROA. Recent news includes a $105M divestiture of ridinilazole to Biossil, sharpening focus on oncology, and upcoming Q2 2026 results on July 23, 2026.
Outlook hinges on clinical success of ivonescimab, with a bullish analyst consensus (66.7% buy ratings) and $15.57 price target suggesting 12% upside. Key risks include binary drug trial outcomes, cash burn from negative operating cash flow, and high short interest creating volatility. Investors face a high-risk, catalyst-driven opportunity dependent on pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
